Group 1 - The company Huahong Hanhlin (02696) announced the appointment of its fourth board of directors, with Dr. Zhu Jun continuing as an executive director and three non-executive directors joining, including prominent figures from Fosun Pharma and former GE Healthcare executives, which will enhance the company's global strategy and innovation pipeline [1] - Huahong Hanhlin has shown strong growth, with six products approved in China and four launched overseas, benefiting over 800,000 patients across more than 50 countries [1] - The company's stock price has increased by over 200% since 2025 and was included in the MSCI Global Small Cap Index in May, indicating rising market recognition [1] Group 2 - The company has made significant progress in its core product pipeline, with the PD-L1 ADC HLX43 for advanced NSCLC receiving approval for international multi-center Phase II clinical trials in multiple countries, and initial dosing completed [2] - The I phase clinical data for HLX43 was presented at the 2025 ASCO annual meeting, showing promising efficacy and safety, with a competitive edge in development [2] - The innovative dual-pathway anti-HER2 monoclonal antibody HLX22 is advancing in international Phase III studies for HER2-positive advanced gastric cancer, and a Phase II trial for HER2 low-expressing HR-positive breast cancer has also commenced [2]
复宏汉霖(02696)CEO朱俊连任执行董事，年内股价涨超200%